Eli Lilly's Q1 Revenue Surges 56%, Hints at More Growth Ahead
Eli Lilly (LLY) posted a 56% revenue increase in Q1 2026, driven by strong demand for its diabetes and obesity drugs. The company raised its full-year guidance, indicating more growth potential.
Key Numbers
Eli Lilly (NYSE: LLY) reported impressive first-quarter results for 2026, with revenue soaring 56% year-over-year. The company surprised analysts by highlighting that there is still substantial room for further growth.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | $12.5B | +56% |
| Net Income | $4.2B | +72% |
| EPS | $4.65 | +70% |
Highlights from the Report
Lilly attributed the strong performance to increased sales of its key drugs, particularly Mounjaro and Zepbound for diabetes and obesity. Management noted that demand continues to outpace supply, leaving significant growth potential.
Guidance
Lilly raised its full-year 2026 revenue guidance to a range of $48-50 billion, up from the prior $45-47 billion. The company also expects margin improvement as production capacity expands.
Stock Reaction
Shares of LLY rose 3.5% in after-hours trading to $890, reflecting investor optimism about sustained growth.
What This Means for Investors
Lilly's results underscore strong fundamental demand for its products, especially in the diabetes and obesity markets. However, investors should monitor the company's ability to ramp up production to meet demand and navigate increasing competition.
Frequently Asked Questions
Found this useful? Share it